latest news releases from the newsroom
Avigen Presents At the 37th Annual Meeting of the Society for Neuroscience
ALAMEDA, Calif., Nov. 4, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapies for the treatment of chronic neurological conditions, today announced the company presented data from a Phase I study of one of its leading pipeline products, AV650 (tolperisone HCl), at the 37th annual meeting of the Society for Neuroscience (SfN) on November 4, 2007 at the San Diego Convention Center in San Diego, California. This Phase I data showed AV650 to be well tolerated with no evidence of sedation.
Dow Jones & Company
Wall Street Journal Circulation Quality Continues Growth
NEW YORK, Nov. 4, 2007 (PRIME NEWSWIRE) -- The Wall Street Journal Online today announces it has reached the historic one million mark for paid subscriptions. In addition, WSJ.com reached a record 10 million unique visitors in October (up 104% from a year ago) and the Wall Street Journal Digital Network, which also includes MarketWatch.com, Barron's Online and AllThingsD.com, hit a record 20 million unique visitors and 454 million page views, up 25% and 37% versus a year ago respectively.
Avigen's AV411 Shows Promising Initial Results for Neuropathic Pain
SALT LAKE CITY, Nov. 3, 2007 (PRIME NEWSWIRE) -- Avigen, Inc. (Nasdaq:AVGN), a biopharmaceutical company innovating therapeutics for neurological care, today announced first-in-patient top line data for its investigational neuropathic pain product, AV411 (ibudilast). The data was presented by Paul Rolan, M.D., FRACP, Professor of Pharmacology, University of Adelaide, Australia, at the 10th International Conference on the Mechanisms and Treatment of Neuropathic Pain held in Salt Lake City, Utah, on Nov. 1-3. Summary data presented at the meeting showed AV411 was safe and well tolerated in this study at doses up to 80 mg/day. The data also indicated a favorable dose to blood plasma level relationship. Although in this preliminary efficacy trial there appears to be no difference in overall mean visual analog scale (VAS) scores between active and placebo arms, a pharmacokinetic assessment indicates an encouraging correlation between AV411 plasma levels and the number of patients that reported a decrease in pain scores as assessed by VAS. Additionally, there was a trend towards decreased opioid use that correlated with increased AV411 dose.